Loading…
← CockpitCompetitor Analysis › WWB Windward Bio Group AGOpen in the cockpit ↗

Windward Bio Group AGWWBCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Mkt cap
$1.31B
US dollars, full cap
$/day
$15.4M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-81.7 pp
WACC 9.1%
Hurdle
n/a
no reverse DCF
Close · USD$22.64
1D-12.1%
1Wn/a
1Mn/a
3Mn/a
6Mn/a
YTDn/a
1Yn/a

What Windward Bio does

No business profile yet.

Windward Bio at a glance

Size Windward Bio (WWB) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.31B, the 2056th largest of 3,085 United States companies the cockpit tracks. Shares closed at $22.64 on 18 Nov 2026.

Capital Return on invested capital runs 81.7 points below its cost of capital (9.1% WACC).

Windward Bio financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025
Revenue$0$0
Revenue growth——
Gross profit-$520,000-$256,000
EBITDA-$72.7M-$51.6M
Net income-$68.2M-$48.3M
Free cash flow-$50.0M-$33.8M
Capital expenditure$20.6M$25.5M
Total debtn/a$306,000

Quarterly statements and history in the cockpit →

Windward Bio competitors and peer comparison

How Windward Bio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Windward Bio against its 20 peers (data as of 18 Nov 2026)
MeasureWWBPeer medianRank in peer set
ROIC minus cost of capital-81.7 pp-1.8 pp2nd lowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%2.2×-17.2%+3.9%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%17.0×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%39.1×n/an/a
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%4.8×3.4%+27.9%
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%2.1×-9.6%+4.6%
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%0.5×n/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a

Questions

Which companies are Windward Bio's closest peers?
The cockpit's peer set: Shanghai OPM Biosciences (688293.SS), MannKind (MNKD), Innoviva (INVA), Ocular Therapeutix (OCUL), Celltrion Pharm (068760.KS), Zhejiang Hisoar Pharmaceutical (002099.SZ), LB Pharmaceuticals (LBRX), Guangdong Taienkang Pharmaceutical (301263.SZ).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.